Octapharma France

Octapharma France company information, Employees & Contact Information

Depuis plus de 40 ans, Octapharma est devenu la plus grande entreprise de fractionnement de plasma privée et indépendante au monde. Avec plus de 11 000 employé.e.s dévoué.e.s, nous fournissons des médicaments de haute qualité qui sauvent des vies, à partir de plasma humain et de lignées cellulaires humaines. Chaque jour, nous travaillons pour améliorer la vie des patients et patientes, créant ainsi un sens profond pour nos donneurs, nos donneuses et nos employé.e.s. Nous soutenons le traitement de patient.e.s dans 120 pays. Nos efforts se concentrent sur trois domaines thérapeutiques : l'immunothérapie, l'hématologie et les soins intensifs. Octapharma exploite sept sites de R&D, cinq sites de production en Autriche, en France, en Allemagne et en Suède, et plus de 190 centres de don de plasma en Europe et aux États-Unis. Au cœur de notre vision se trouve un objectif clair : fournir de nouvelles solutions de santé qui font progresser la vie humaine. Nous savons que notre travail change la vie de millions de personnes. Nous ressentons le pouvoir de l'espoir et nous nous efforçons chaque jour de le transmettre. Ensemble, nous contribuons à un objectif plus grand - où nous faisons toutes et tous partie d'une chaîne vitale. Nos sites en France : 📍 Octapharma S.AS, Lingolsheim, France 📍 Octapharma France S.A.S, Paris, France Community Guidelines : https://bit.ly/3M8ioml

Company Details

Employees
386
Founded
-
Address
72 Rue Du Maréchal Foch, Lingolsheim,alsace 67380,france
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Lingolsheim, Alsace
Looking for a particular Octapharma France employee's phone or email?

Octapharma France Questions

News

Octapharma Releases Results for Phase 3 Superiority Study of Pediatric Acute-onset Neuropsychiatric Syndrome - PR Newswire

Octapharma Releases Results for Phase 3 Superiority Study of Pediatric Acute-onset Neuropsychiatric Syndrome PR Newswire

$2.55M Octapharma Plasma data breach class action settlement - Class Action Lawsuits

$2.55M Octapharma Plasma data breach class action settlement Class Action Lawsuits

Octapharma USA: JAMA Publishes Results for Investigational Four-Factor Prothrombin Complex Concentrate in Cardiac Surgical Bleeding - PR Newswire

Octapharma USA: JAMA Publishes Results for Investigational Four-Factor Prothrombin Complex Concentrate in Cardiac Surgical Bleeding PR Newswire

A Major Clinical Trial Could Revolutionize Trauma Care for Life-Threatening Bleeding - CU Anschutz newsroom

A Major Clinical Trial Could Revolutionize Trauma Care for Life-Threatening Bleeding CU Anschutz newsroom

Newly opened Kentwood plasma donation center helping save lives while providing income for donors - FOX 17 West Michigan News

Newly opened Kentwood plasma donation center helping save lives while providing income for donors FOX 17 West Michigan News

Plasma donation center in Kentwood celebrates opening - woodtv.com

Plasma donation center in Kentwood celebrates opening woodtv.com

Octapharma secures FDA nod for warfarin reversal agent Balfaxar - Fierce Pharma

Octapharma secures FDA nod for warfarin reversal agent Balfaxar Fierce Pharma

Octapharma Plasma opens fourth Central California location - ABC30 Fresno

Octapharma Plasma opens fourth Central California location ABC30 Fresno

News | New Pay-for-Blood Plasma Business Coming to Providence - Elected Official Warns of “Exploitation” - GoLocalProv

News | New Pay-for-Blood Plasma Business Coming to Providence - Elected Official Warns of “Exploitation” GoLocalProv

FDA Approves Expanded Indication for Octapharma’s Fibryga for Patients Experiencing Bleeding Due to Acquired Fibrinogen Deficiency - Pharmaceutical Executive

FDA Approves Expanded Indication for Octapharma’s Fibryga for Patients Experiencing Bleeding Due to Acquired Fibrinogen Deficiency Pharmaceutical Executive

Octapharma Plasma expanding U.S. HQ with $18.75M building acquisition - The Business Journals

Octapharma Plasma expanding U.S. HQ with $18.75M building acquisition The Business Journals

Octapharma USA to present clinical overview of dermatomyositis during The Myositis Association’s Annual Conference - EurekAlert!

Octapharma USA to present clinical overview of dermatomyositis during The Myositis Association’s Annual Conference EurekAlert!

Octapharma Plasma Launches Pilot To Get Paid In Bitcoin For Plasma Donations - Bitcoin Magazine

Octapharma Plasma Launches Pilot To Get Paid In Bitcoin For Plasma Donations Bitcoin Magazine

Octapharma USA Receives FDA Emergency Use Authorization for octaplasLG Powder, Allows U.S. Military Medical Providers Emergent Use in Treatment of Hemorrhage or Coagulopathy - PR Newswire

Octapharma USA Receives FDA Emergency Use Authorization for octaplasLG Powder, Allows U.S. Military Medical Providers Emergent Use in Treatment of Hemorrhage or Coagulopathy PR Newswire

Octapharma Announces Availability of Balfaxar® For Warfarin Reversal in Urgent Surgery & Invasive Procedures - PR Newswire

Octapharma Announces Availability of Balfaxar® For Warfarin Reversal in Urgent Surgery & Invasive Procedures PR Newswire

Octapharma USA: FDA Grants Expanded Approval to wilate® as the First VWF Concentrate for Prophylaxis in All Types of VWD - PR Newswire

Octapharma USA: FDA Grants Expanded Approval to wilate® as the First VWF Concentrate for Prophylaxis in All Types of VWD PR Newswire

Octapharma USA: FDA Grants Orphan Drug Exclusivity to wilate®, the First VWF Concentrate for Prophylaxis in All Types of VWD - PR Newswire

Octapharma USA: FDA Grants Orphan Drug Exclusivity to wilate®, the First VWF Concentrate for Prophylaxis in All Types of VWD PR Newswire

FDA Approves Additional Indication for Fibryga® for Fibrinogen Supplementation in Bleeding Patients with Acquired Fibrinogen Deficiency, Potentially Ushering in a New Standard of Care - PR Newswire

FDA Approves Additional Indication for Fibryga® for Fibrinogen Supplementation in Bleeding Patients with Acquired Fibrinogen Deficiency, Potentially Ushering in a New Standard of Care PR Newswire

Octapharma USA Requests FDA Approval for wilate® VWD Prophylaxis Supplement - PR Newswire

Octapharma USA Requests FDA Approval for wilate® VWD Prophylaxis Supplement PR Newswire

Octapharma's Prothrombin Complex Concentrate, Balfaxar®, Receives FDA Approval For Warfarin Reversal in Urgent Surgery & Invasive Procedures - PR Newswire

Octapharma's Prothrombin Complex Concentrate, Balfaxar®, Receives FDA Approval For Warfarin Reversal in Urgent Surgery & Invasive Procedures PR Newswire

FDA approves Octapharma's Octagam® 10% for adult dermatomyositis - EurekAlert!

FDA approves Octapharma's Octagam® 10% for adult dermatomyositis EurekAlert!

Octapharma Uses IVIG as Potential Treatment for COVID-19 - BioSpace

Octapharma Uses IVIG as Potential Treatment for COVID-19 BioSpace

FDA Approves Octapharma’s cutaquig® 16.5% for Pediatric PI Patients, Providing Flexible Treatment Options - BioSpace

FDA Approves Octapharma’s cutaquig® 16.5% for Pediatric PI Patients, Providing Flexible Treatment Options BioSpace

Exclusive: BlackSuit ransomware gang claims hack on Octapharma Plasma - Cyber Daily

Exclusive: BlackSuit ransomware gang claims hack on Octapharma Plasma Cyber Daily

As Omicron Spreads Nationally, Octapharma’s fibryga® & Octaplas™ Become Increasingly Important Replacement Therapies - BioSpace

As Omicron Spreads Nationally, Octapharma’s fibryga® & Octaplas™ Become Increasingly Important Replacement Therapies BioSpace

Octapharma USA Sponsors Educational National Conference for Type 3 Von Willebrand Disease Patients - PR Newswire

Octapharma USA Sponsors Educational National Conference for Type 3 Von Willebrand Disease Patients PR Newswire

Blood money: Octapharma facility, offering cash for plasma, pops up in Brockton - Enterprise News

Blood money: Octapharma facility, offering cash for plasma, pops up in Brockton Enterprise News

FDA Clears Freeze-Dried Plasma Transfusion Powder for Military Emergency Use - The Defense Post

FDA Clears Freeze-Dried Plasma Transfusion Powder for Military Emergency Use The Defense Post

10% Receives 7 Years of Market Exclusivity for Adult Dermatomyositis - Business Wire

10% Receives 7 Years of Market Exclusivity for Adult Dermatomyositis Business Wire

Octapharma Group Reports Strong Results for 2018 - BioSpace

Octapharma Group Reports Strong Results for 2018 BioSpace

FDA Extends Shelf Life of Octapharma’s cutaquig® 16.5% for Adult PI Patients - Business Wire

FDA Extends Shelf Life of Octapharma’s cutaquig® 16.5% for Adult PI Patients Business Wire

Octapharma ordered to pay $105K after terminating worker who needed accommodation to care for cancer-stricken mom - HR Law Canada

Octapharma ordered to pay $105K after terminating worker who needed accommodation to care for cancer-stricken mom HR Law Canada

joliark restores abandoned stockholm brewery for octapharma - Designboom

joliark restores abandoned stockholm brewery for octapharma Designboom

Octapharma goes for Schreiner MediPharm automatic dispensing system - Emballage Digest

Octapharma goes for Schreiner MediPharm automatic dispensing system Emballage Digest

Octapharma Brewery - Domus Web

Octapharma Brewery Domus Web

Octapharma Plasma Pay Chart (Up to $1,000 for New Donors in 2025) - MoneyPantry.com

Octapharma Plasma Pay Chart (Up to $1,000 for New Donors in 2025) MoneyPantry.com

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant